EfficacyAnnamycin's complete remission rate in second-line patients is 50%, significantly higher than the 20%-25% range for approved therapies.
Regulatory SupportGiven the compelling data and lack of cardiotoxicity, regulators are expected to be supportive of a path to a pivotal trial.
SafetyOver 82 patients across 5 clinical trials have not experienced cardiotoxicity, supporting the likelihood of regulatory approval for a pivotal trial.